Jarne Elleholm

Aqualife A/S engages in the provision of logistical solutions for the fishing industry. It focuses on the transportation of fresh seafoods and live aquatic animals through its logistic system which includes freight, equipment, and services. The firm also engages in the establishment of land-based infrastructure for storage, cooling, and acclimatization. The company was founded by Maja Wall and Lars Nannerup on April 1, 2001 and is headquartered in Hellerup, Denmark.

Danmarks Eksport- og Investeringsfond (EIFO) is a venture capital subsidiary of Government of Denmark and founded in 1992. The firm is headquartered in Hellerup, Denmark.

Zoetis Denmark ApS designs and manufactures diagnostic cartridges based on micro fluidic technology. Its technology enables veterinarians to obtain critical diagnostic information on their patients. The company was founded in 2000 and is headquartered in Farum, Denmark.

LiPlasome Pharma A/S develops, produces and supplies drugs for chemotherapy treatment. It has developed a technology based on incapsulation of chemotherapy in liposomes (fatty molecules) that will only dissolve in and around cancer tissue (tumors or metastases). The firm’s technology will improve chemotherapy treatment within a wide range of cancer diseases significantly as it improves the balance between effect and side effects. LiPlasome’s first drug candicate LiplaCis which is a liposonal formulation of Cisplatin, is in clinical phase 1. The company was founded in January 2001 by Ole Gunner Mouritsen and is headquartered in Hoersholm, Denmark.

Inventure Capital A/S is a venture capital firm based in Aarhus, Denmark. Founded in 2006, the firm was established to manage several early-stage technology funds, namely INCUBA Venture, InnFond and Syddansk Kapital.

Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis.

Medotech A/S is a Danish biotech company with unique skills within the development and design of medical devices. Medotech's core competence is development of customised devices to register and analyse signals from the human body. The result of the analysis is returned to the body as bio-feedback. Medotech develops its solutions in cooperation with development departments, research institutes and other business partners in order to be able to supply professionally well- founded and thoroughly tested end products. Medotech's main product, GRINDCARE, has been developed in close cooperation with the Danish Technological Institute and the School of Dentistry at the University of Aarhus and a number of high-tech enterprises in Denmark. Medotech was founded by Faramarz Jadidi and is owned by a number of private and financial investors.

RSP Systems A/S provides non-invasive solutions for sugar and insulin blood level measurements. Its products are used to make measurements of molecules in terms of identification and quantities. The company was founded by Olav Storm Kjestrup, Stefan Banke, and Morten Henneberg in May 2006 and is headquartered in Odense, Denmark

Lundbeck Ltd. engages in the research, development, production, marketing and sale of pharmaceuticals. It provides services that aid in the treatment of CNS disorders, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy and insomnia. The company was founded in 1972 and is headquartered in St. Albans, the United Kingdom.